PIK3CA and inflammatory breast carcinoma: PIK3CA/AKT/mTOR was the only pathway showing a significant difference, which was more frequently altered in metastatic IBC compared with nonmetastatic IBC (48.0% vs. 24.1%, p = 0.003).